Omega Biosystems Incorporated

Biotech · Acquired

High-throughput flow cytometry platform enabling single-cell phenotypic analysis of drug compounds during primary screening

Grants
$1.9M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
8
4 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Radiofrequency-multiplexed parallel flow cytometer for high content screening and drug discovery$349,919
Federal grantDepartment of Health and Human Services · Phase I · Radiofrequency-multiplexed parallel flow cytometer for high content screening and drug discovery$349,868
Federal grantNational Science Foundation · Phase II · SBIR Phase II: Imaging Flow Cytometer for High-Throughput High-Content Screening$749,999
Federal grantDepartment of Health and Human Services · Phase I · Image-based cell sorting using a high throughput fluorescence imaging flow cytometer$225,000
Federal grantDepartment of Health and Human Services · Phase I · Image-based cell sorting using a high throughput fluorescence imaging flow cytometer$225,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1414DeNovoTherapies LLC——
1415Op-T-Mune, Inc——
1416COGENTIS THERAPEUTICS INC——
1417Omega Biosystems Incorporated——
1418Omm Scientific, Inc——
1419EVODENOVO INC——
1420Link Biosystems Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 4 granted of 8

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.